RSS Newsfeeds

See all RSS Newsfeeds

Global Regions

North America ( XML Feed )

Oct 4, 2016 4:05 PM ET

Archived: Avagenesis Increases Previously Announced Private Placement to Include Executives of the Company

Disclosure NewswireTM

iCrowdNewswire - Oct 4, 2016


Calgary, Alberta – Avagenesis Corp. (TSXV: VVA) (“Avagenesis” or “Company”) announces that the Company will increase the non-brokered private placement previously announced on September 30, 2016 from $130,000* to $230,000 at $0.25 per share to include the Company’s top three executives, Norman Tsui, Director and CEO, Alan Tam, CFO, and Jasmine Chiu, Director and VP.


These securities were acquired for individual investment purposes only.  All securities issued under the Private Placement will be subject to a hold period expiring four months and one day from the date of issuance.


The Private Placement is subject to TSX Venture Exchange (“Exchange”) final acceptance.


*Subject to final foreign exchange rate.


About Avagenesis Corp.


Avagenesis is a biotechnology company engaged in the commercialization of licensed cell isolation medical technologies for use in regenerative medical aesthetics, wound management and non-healing wounds, cardiovascular and heart diseases, peripheral arterial disease, critical limb ischemia or diabetic leg, hepatic disease and kidney disease.


Neither the TSX Venture Exchange nor their respective regulation services providers (as that term is defined in their respective policies) accepts responsibility for the adequacy or accuracy of this press release.


Cautionary Statements


Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “likely”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on current belief or assumptions as to the outcome and timing of such future events. Actual future results and developments may differ materially from those contemplated by these statements depending on, among other things, the risk that the Company may not successfully transition to a clinical stage company and successfully execute its development and commercialization activities. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the Company. Readers are cautioned that the above list of risk factors is not exhaustive. The forward-looking information contained in this press release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.


For further information, please contact:


Avagenesis Corp.

Alan Tam, CPA, CA

Chief Financial Officer

Telephone: (604) 377-7575


Contact Information:

Alan Tam, CPA, CA
(604) 377-7575

View Related News >